Nuwellis Inc vs Novo Nordisk A/S — how do they compare? Nuwellis Inc trades at $1.49 (market cap $542.80K), while Novo Nordisk A/S trades at $45.96 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 382921.9× Nuwellis Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | NVO | |
|---|---|---|
Market Cap | $542.80K | $207.85B |
Sector | Technology | Health |
52-Week High | $220.50 | $63.98 |
52-Week Low | $1.42 | $35.29 |
Enterprise Value | -$1.27M | $222.55B |
Dividend Yield | — | 3.81% |
Trailing returns across standard periods
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →